Actively Recruiting
Prospective Observational Cohort Study of Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer Receiving Osimertinib With or Without Chemotherapy
Led by N-Power Medicine · Updated on 2026-09-22
130
Participants Needed
10
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are building a prospective group of patients with locally advanced or metastatic non-small cell lung cancer NSCLC who have common EGFR mutations, specifically EGFR exon 19del or exon 21 L858R. The study focuses on patients diagnosed on or after January 1, 2024, and aims to collect standardized data at key points before treatment starts, during treatment, and when treatment ends. The main goal is to observe real-world progression-free survival among those treated with first-line osimertinib. Participants may receive osimertinib combined with chemotherapy or other treatment regimens initiated after January 1, 2024, or osimertinib alone as monotherapy for newly diagnosed metastatic NSCLC. About 30% of patients enrolling before starting osimertinib will have imaging done at set intervals to monitor disease progression. Treatments are given as part of routine clinical care without experimental procedures. Throughout the study, data will be collected at baseline, during treatment, and at therapy discontinuation. Researchers will assess progression-free survival, overall survival, and time to stopping treatment, tracking these outcomes up to 100 months from treatment start. Participants are observed in a real-world setting, with no investigational drugs administered, and the study will continue until April 2029.
CONDITIONS
Brief Title
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Research Team
N
N-Power Medicine Support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here